PSMA PET/CT: Joint EANM Procedure Guideline/SNMMI Procedure Standard for Prostate Cancer Imaging 2.0

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2023 Jan 5

PMID 36604326

Authors

Wolfgang P Fendler

Matthias Eiber

Mohsen Beheshti

Jamshed Bomanji

Jeremie Calais

Francesco Ceci

Steve Y Cho

Stefano Fanti

Frederik L Giesel

Karolien Goffin

Uwe Haberkorn

Heather Jacene

Phillip J Koo

Klaus Kopka

Bernd J Krause

Liza Lindenberg

Charles Marcus

Felix M Mottaghy

Daniela E Oprea-Lager

Joseph R Osborne

Morand Piert

Steven P Rowe

Heiko Schoder

Simon Wan

Hans-Jurgen Wester

Thomas A Hope

Ken Herrmann

Affiliations

Soon will be listed here.

Abstract

Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the clinical use of PSMA-ligand PET/CT are discussed. This document provides clinicians and technicians with the best available evidence, to support the implementation of PSMA PET/CT imaging in research and routine practice.

Citing Articles

In-silico structural and functional analysis of nonsynonymous single nucleotide polymorphisms in human gene.

Tondar A, Irfan M, Sanchez-Herrero S, Athar H, Haqqi A, Bepari A In Silico Pharmacol. 2025; 13(1):32.

PMID: 40018382 PMC: 11861814. DOI: 10.1007/s40203-025-00319-3.

Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).

Guo X, Li S Oncol Rep. 2025; 53(4).

PMID: 39981932 PMC: 11865881. DOI: 10.3892/or.2025.8879.

Comparison of Cu-DOTA-PSMA-3Q and Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging.

Liu H, Zhang X, Zhang J, Pan Y, Wen H, Xu X Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39954062 DOI: 10.1007/s00259-025-07131-3.

Association of [Ga]Ga-PSMA-11 PET/CT Metrics with PSA Persistence Following Radical Prostatectomy in Patients with Intermediate- and High-Risk Prostate Cancer.

Rosales J, Betech-Antar V, Minguez F, Guillen E, Prieto E, Quincoces G Diagnostics (Basel). 2025; 15(3).

PMID: 39941231 PMC: 11817176. DOI: 10.3390/diagnostics15030301.

Vesicles Secreted by Renal Cell Carcinoma Cells Cause Vascular Endothelial Cells to Express PSMA and Drive Tumor Progression.

Watanabe R, Kagimoto K, Chosei M, Sakaue T, Kurata M, Miura N Cells. 2025; 14(3).

PMID: 39936957 PMC: 11817738. DOI: 10.3390/cells14030165.

References

Silver D, Pellicer I, Fair W, Heston W, Cordon-Cardo C . Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997; 3(1):81-5. View

Bostwick D, Pacelli A, Blute M, Roche P, Murphy G . Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998; 82(11):2256-61. DOI: 10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s. View

Mannweiler S, Amersdorfer P, Trajanoski S, Terrett J, King D, Mehes G . Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2008; 15(2):167-72. DOI: 10.1007/s12253-008-9104-2. View

Yao V, Bacich D . Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate. 2006; 66(8):867-75. DOI: 10.1002/pros.20361. View

Sheehan B, Guo C, Neeb A, Paschalis A, Sandhu S, de Bono J . Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. Eur Urol Focus. 2021; 8(5):1157-1168. DOI: 10.1016/j.euf.2021.06.006. View

Ghosh A, Heston W . Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004; 91(3):528-39. DOI: 10.1002/jcb.10661. View

Ross J, Sheehan C, Fisher H, Kaufman Jr R, Kaur P, Gray K . Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003; 9(17):6357-62. View

Paschalis A, Sheehan B, Riisnaes R, Nava Rodrigues D, Gurel B, Bertan C . Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. Eur Urol. 2019; 76(4):469-478. PMC: 6853166. DOI: 10.1016/j.eururo.2019.06.030. View

Boellaard R, Delgado-Bolton R, Oyen W, Giammarile F, Tatsch K, Eschner W . FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014; 42(2):328-54. PMC: 4315529. DOI: 10.1007/s00259-014-2961-x. View

10.

Banerjee S, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox J . 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010; 53(14):5333-41. PMC: 3341619. DOI: 10.1021/jm100623e. View

11.

Chen Y, Pullambhatla M, Foss C, Byun Y, Nimmagadda S, Senthamizhchelvan S . 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011; 17(24):7645-53. PMC: 3243762. DOI: 10.1158/1078-0432.CCR-11-1357. View

12.

Eder M, Schafer M, Bauder-Wust U, Hull W, Wangler C, Mier W . 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23(4):688-97. DOI: 10.1021/bc200279b. View

13.

Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart H, Hadaschik B . PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2012; 40(4):486-95. DOI: 10.1007/s00259-012-2298-2. View

14.

Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels O . The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. J Nucl Med. 2015; 56(11):1697-705. DOI: 10.2967/jnumed.115.161299. View

15.

Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester H, Czernin J . Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015; 56(6):855-61. PMC: 5003538. DOI: 10.2967/jnumed.115.156133. View

16.

Szabo Z, Mena E, Rowe S, Plyku D, Nidal R, Eisenberger M . Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol. 2015; 17(4):565-74. PMC: 4531836. DOI: 10.1007/s11307-015-0850-8. View

17.

Giesel F, Cardinale J, Schafer M, Neels O, Benesova M, Mier W . (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur J Nucl Med Mol Imaging. 2016; 43(10):1929-30. PMC: 4969351. DOI: 10.1007/s00259-016-3447-9. View

18.

Oh S, Wurzer A, Teoh E, Oh S, Langbein T, Kronke M . Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, F-rhPSMA-7, in Patients with Prostate Cancer. J Nucl Med. 2019; 61(5):702-709. PMC: 7198378. DOI: 10.2967/jnumed.119.234609. View

19.

Cho S, Gage K, Mease R, Senthamizhchelvan S, Holt D, Jeffrey-Kwanisai A . Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012; 53(12):1883-91. PMC: 3742115. DOI: 10.2967/jnumed.112.104661. View

20.

Giesel F, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M . Intraindividual Comparison of F-PSMA-1007 and F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med. 2017; 59(7):1076-1080. DOI: 10.2967/jnumed.117.204669. View